NASDAQ:ATRI

Atrion Competitors

$669.80
+12.80 (+1.95 %)
(As of 04/16/2021 12:00 AM ET)
Add
Compare
Today's Range
$659.44
Now: $669.80
$669.80
50-Day Range
$619.20
MA: $647.96
$685.00
52-Week Range
$567.00
Now: $669.80
$745.00
Volume3,005 shs
Average Volume8,102 shs
Market Capitalization$1.22 billion
P/E Ratio37.74
Dividend Yield1.08%
Beta0.13

Competitors

Atrion (NASDAQ:ATRI) Vs. ALGN, WST, COO, XRAY, HAE, and STAA

Should you be buying ATRI stock or one of its competitors? Companies in the sub-industry of "health care supplies" are considered alternatives and competitors to Atrion, including Align Technology (ALGN), West Pharmaceutical Services (WST), The Cooper Companies (COO), DENTSPLY SIRONA (XRAY), Haemonetics (HAE), and STAAR Surgical (STAA).

Atrion (NASDAQ:ATRI) and Align Technology (NASDAQ:ALGN) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, valuation, institutional ownership, profitability, earnings and dividends.

Insider and Institutional Ownership

63.2% of Atrion shares are owned by institutional investors. Comparatively, 85.8% of Align Technology shares are owned by institutional investors. 22.4% of Atrion shares are owned by insiders. Comparatively, 1.2% of Align Technology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Volatility & Risk

Atrion has a beta of 0.13, meaning that its share price is 87% less volatile than the S&P 500. Comparatively, Align Technology has a beta of 1.68, meaning that its share price is 68% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Atrion and Align Technology, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Atrion0000N/A
Align Technology13902.62

Align Technology has a consensus target price of $502.1667, indicating a potential downside of 17.18%. Given Align Technology's higher probable upside, analysts plainly believe Align Technology is more favorable than Atrion.

Valuation & Earnings

This table compares Atrion and Align Technology's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Atrion$155.07 million7.90$36.76 millionN/AN/A
Align Technology$2.41 billion19.94$442.78 million$4.96122.24

Align Technology has higher revenue and earnings than Atrion.

Profitability

This table compares Atrion and Align Technology's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Atrion21.90%13.90%12.55%
Align Technology76.00%68.99%46.64%

Summary

Align Technology beats Atrion on 10 of the 12 factors compared between the two stocks.

Atrion (NASDAQ:ATRI) and West Pharmaceutical Services (NYSE:WST) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, valuation, institutional ownership, profitability, earnings and dividends.

Institutional & Insider Ownership

63.2% of Atrion shares are owned by institutional investors. Comparatively, 92.6% of West Pharmaceutical Services shares are owned by institutional investors. 22.4% of Atrion shares are owned by company insiders. Comparatively, 1.6% of West Pharmaceutical Services shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Volatility & Risk

Atrion has a beta of 0.13, indicating that its stock price is 87% less volatile than the S&P 500. Comparatively, West Pharmaceutical Services has a beta of 1.13, indicating that its stock price is 13% more volatile than the S&P 500.

Dividends

Atrion pays an annual dividend of $7.00 per share and has a dividend yield of 1.0%. West Pharmaceutical Services pays an annual dividend of $0.68 per share and has a dividend yield of 0.2%. West Pharmaceutical Services pays out 21.0% of its earnings in the form of a dividend. Atrion has increased its dividend for 17 consecutive years and West Pharmaceutical Services has increased its dividend for 25 consecutive years.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Atrion and West Pharmaceutical Services, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Atrion0000N/A
West Pharmaceutical Services01202.67

West Pharmaceutical Services has a consensus target price of $310.00, indicating a potential downside of 1.22%. Given West Pharmaceutical Services' higher probable upside, analysts plainly believe West Pharmaceutical Services is more favorable than Atrion.

Valuation & Earnings

This table compares Atrion and West Pharmaceutical Services' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Atrion$155.07 million7.90$36.76 millionN/AN/A
West Pharmaceutical Services$1.84 billion12.60$241.70 million$3.2496.86

West Pharmaceutical Services has higher revenue and earnings than Atrion.

Profitability

This table compares Atrion and West Pharmaceutical Services' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Atrion21.90%13.90%12.55%
West Pharmaceutical Services14.69%19.01%12.78%

Summary

West Pharmaceutical Services beats Atrion on 11 of the 15 factors compared between the two stocks.

Atrion (NASDAQ:ATRI) and The Cooper Companies (NYSE:COO) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, valuation, institutional ownership, profitability, earnings and dividends.

Institutional & Insider Ownership

63.2% of Atrion shares are owned by institutional investors. Comparatively, 95.8% of The Cooper Companies shares are owned by institutional investors. 22.4% of Atrion shares are owned by company insiders. Comparatively, 1.4% of The Cooper Companies shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Volatility & Risk

Atrion has a beta of 0.13, indicating that its stock price is 87% less volatile than the S&P 500. Comparatively, The Cooper Companies has a beta of 0.82, indicating that its stock price is 18% less volatile than the S&P 500.

Dividends

Atrion pays an annual dividend of $7.00 per share and has a dividend yield of 1.0%. The Cooper Companies pays an annual dividend of $0.06 per share and has a dividend yield of 0.0%. The Cooper Companies pays out 0.6% of its earnings in the form of a dividend. Atrion has increased its dividend for 17 consecutive years and The Cooper Companies has increased its dividend for 1 consecutive years. Atrion is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Atrion and The Cooper Companies, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Atrion0000N/A
The Cooper Companies04602.60

The Cooper Companies has a consensus target price of $384.25, indicating a potential downside of 3.82%. Given The Cooper Companies' higher probable upside, analysts plainly believe The Cooper Companies is more favorable than Atrion.

Valuation & Earnings

This table compares Atrion and The Cooper Companies' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Atrion$155.07 million7.90$36.76 millionN/AN/A
The Cooper Companies$2.43 billion8.08$238.40 million$9.6441.44

The Cooper Companies has higher revenue and earnings than Atrion.

Profitability

This table compares Atrion and The Cooper Companies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Atrion21.90%13.90%12.55%
The Cooper Companies9.81%12.79%7.20%

Summary

The Cooper Companies beats Atrion on 8 of the 15 factors compared between the two stocks.

Atrion (NASDAQ:ATRI) and DENTSPLY SIRONA (NASDAQ:XRAY) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, valuation, institutional ownership, profitability, earnings and dividends.

Institutional & Insider Ownership

63.2% of Atrion shares are owned by institutional investors. Comparatively, 96.0% of DENTSPLY SIRONA shares are owned by institutional investors. 22.4% of Atrion shares are owned by company insiders. Comparatively, 0.5% of DENTSPLY SIRONA shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Dividends

Atrion pays an annual dividend of $7.00 per share and has a dividend yield of 1.0%. DENTSPLY SIRONA pays an annual dividend of $0.40 per share and has a dividend yield of 0.6%. DENTSPLY SIRONA pays out 16.3% of its earnings in the form of a dividend. Atrion has increased its dividend for 17 consecutive years and DENTSPLY SIRONA has increased its dividend for 1 consecutive years. Atrion is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Volatility & Risk

Atrion has a beta of 0.13, indicating that its stock price is 87% less volatile than the S&P 500. Comparatively, DENTSPLY SIRONA has a beta of 0.98, indicating that its stock price is 2% less volatile than the S&P 500.

Valuation & Earnings

This table compares Atrion and DENTSPLY SIRONA's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Atrion$155.07 million7.90$36.76 millionN/AN/A
DENTSPLY SIRONA$4.03 billion3.56$262.90 million$2.4526.70

DENTSPLY SIRONA has higher revenue and earnings than Atrion.

Profitability

This table compares Atrion and DENTSPLY SIRONA's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Atrion21.90%13.90%12.55%
DENTSPLY SIRONA-1.40%7.13%4.13%

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Atrion and DENTSPLY SIRONA, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Atrion0000N/A
DENTSPLY SIRONA15702.46

DENTSPLY SIRONA has a consensus target price of $55.3333, indicating a potential downside of 15.42%. Given DENTSPLY SIRONA's higher probable upside, analysts plainly believe DENTSPLY SIRONA is more favorable than Atrion.

Summary

Atrion beats DENTSPLY SIRONA on 9 of the 15 factors compared between the two stocks.

Haemonetics (NYSE:HAE) and Atrion (NASDAQ:ATRI) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, profitability, earnings, analyst recommendations, institutional ownership and dividends.

Insider and Institutional Ownership

96.2% of Haemonetics shares are owned by institutional investors. Comparatively, 63.2% of Atrion shares are owned by institutional investors. 1.6% of Haemonetics shares are owned by company insiders. Comparatively, 22.4% of Atrion shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Risk & Volatility

Haemonetics has a beta of 0.56, indicating that its stock price is 44% less volatile than the S&P 500. Comparatively, Atrion has a beta of 0.13, indicating that its stock price is 87% less volatile than the S&P 500.

Valuation and Earnings

This table compares Haemonetics and Atrion's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Haemonetics$988.48 million6.01$76.53 million$3.3135.34
Atrion$155.07 million7.90$36.76 millionN/AN/A

Haemonetics has higher revenue and earnings than Atrion.

Profitability

This table compares Haemonetics and Atrion's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Haemonetics11.76%22.85%10.40%
Atrion21.90%13.90%12.55%

Analyst Ratings

This is a breakdown of current recommendations for Haemonetics and Atrion, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Haemonetics00403.00
Atrion0000N/A

Haemonetics presently has a consensus target price of $144.80, indicating a potential upside of 23.79%. Given Haemonetics' higher probable upside, analysts plainly believe Haemonetics is more favorable than Atrion.

Summary

Haemonetics beats Atrion on 8 of the 12 factors compared between the two stocks.

STAAR Surgical (NASDAQ:STAA) and Atrion (NASDAQ:ATRI) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, profitability, earnings, analyst recommendations, institutional ownership and dividends.

Insider and Institutional Ownership

85.4% of STAAR Surgical shares are owned by institutional investors. Comparatively, 63.2% of Atrion shares are owned by institutional investors. 3.9% of STAAR Surgical shares are owned by company insiders. Comparatively, 22.4% of Atrion shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Risk & Volatility

STAAR Surgical has a beta of 1.09, indicating that its stock price is 9% more volatile than the S&P 500. Comparatively, Atrion has a beta of 0.13, indicating that its stock price is 87% less volatile than the S&P 500.

Valuation and Earnings

This table compares STAAR Surgical and Atrion's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
STAAR Surgical$150.18 million36.65$14.05 million$0.46256.98
Atrion$155.07 million7.90$36.76 millionN/AN/A

Atrion has higher revenue and earnings than STAAR Surgical.

Profitability

This table compares STAAR Surgical and Atrion's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
STAAR Surgical5.73%8.99%7.12%
Atrion21.90%13.90%12.55%

Analyst Ratings

This is a breakdown of current recommendations for STAAR Surgical and Atrion, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
STAAR Surgical03302.50
Atrion0000N/A

STAAR Surgical presently has a consensus target price of $68.50, indicating a potential downside of 42.05%. Given STAAR Surgical's higher probable upside, analysts plainly believe STAAR Surgical is more favorable than Atrion.


Atrion Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Align Technology logo
ALGN
Align Technology
1.9$606.33+0.0%$47.98 billion$2.41 billion27.59Analyst Report
News Coverage
West Pharmaceutical Services logo
WST
West Pharmaceutical Services
1.9$313.83+0.9%$23.18 billion$1.84 billion82.80
The Cooper Companies logo
COO
The Cooper Companies
1.9$399.52+0.1%$19.64 billion$2.43 billion83.06Insider Selling
DENTSPLY SIRONA logo
XRAY
DENTSPLY SIRONA
2.0$65.42+0.9%$14.33 billion$4.03 billion-284.43Decrease in Short Interest
Haemonetics logo
HAE
Haemonetics
1.6$116.97+1.4%$5.94 billion$988.48 million56.51
STAAR Surgical logo
STAA
STAAR Surgical
1.4$118.21+1.4%$5.50 billion$150.18 million622.19Increase in Short Interest
Quidel logo
QDEL
Quidel
2.4$128.83+2.2%$5.45 billion$534.89 million15.12
Neogen logo
NEOG
Neogen
1.2$94.80+2.0%$5.07 billion$418.17 million83.16Insider Selling
ICU Medical logo
ICUI
ICU Medical
1.5$211.70+1.6%$4.49 billion$1.27 billion56.01Insider Selling
News Coverage
Merit Medical Systems logo
MMSI
Merit Medical Systems
1.5$61.78+0.7%$3.44 billion$994.85 million-116.56
Cerus logo
CERS
Cerus
1.7$6.18+2.8%$1.04 billion$74.65 million-15.85
Meridian Bioscience logo
VIVO
Meridian Bioscience
1.7$23.25+1.4%$1.00 billion$253.67 million21.53
OraSure Technologies logo
OSUR
OraSure Technologies
1.7$10.01+0.0%$720.18 million$154.60 million-43.52
Antares Pharma logo
ATRS
Antares Pharma
1.8$4.01+3.0%$674.33 million$123.86 million66.84
Anika Therapeutics logo
ANIK
Anika Therapeutics
1.5$40.21+1.6%$576.21 million$114.51 million-85.55News Coverage
Utah Medical Products logo
UTMD
Utah Medical Products
0.9$87.50+0.4%$319.03 million$46.90 million27.60Upcoming Earnings
News Coverage
This page was last updated on 4/16/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.